{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"APVO","limit":50},"count":50,"signals":[{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"t: of four evaluable patients who had AML and were treated with mipletamig as a single agent, one patient achieved MLFS and three achieved SD as their best overall response. In Cohort 5 (CR upon enrollment based on design criteria), two enrolled patients (N=2) maintained their disease status as best overall response compared to baseline for two months and three months. In addition, in Cohort 2 of th","filed_date":"2026-03-26","accession":"0001193125-26-126278","full_text":"https://origin.rootz.global/static/filing/0001193125-26-126278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":76,"context":"ects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not effectively carry out their contractual duties, comply with re","filed_date":"2026-03-26","accession":"0001193125-26-126278","full_text":"https://origin.rootz.global/static/filing/0001193125-26-126278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"ows for 2025 and 2024 compensation awarded to or paid to, or earned by, the Company's Chief Executive Officer and its two other most highly compensated executive officers as of December 31, 2025 (the named executive officers). | | | Name and Principal Position | | Year | | Salary | | | Bonus (4) | | | EquityAwards(1) | | | Non-Equity Incentive Plan Compensation(2) | | | All OtherCompensation(3) | | |","filed_date":"2026-03-26","accession":"0001193125-26-126278","full_text":"https://origin.rootz.global/static/filing/0001193125-26-126278.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2025-11-06","accession":"0001193125-25-269598","full_text":"https://origin.rootz.global/static/filing/0001193125-25-269598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2025-08-11","accession":"0000950170-25-106247","full_text":"https://origin.rootz.global/static/filing/0000950170-25-106247.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":61,"context":"tics Inc. Third Amended and Restated 2018 Stock Incentive Plan (Proposal 5 or the Stock Incentive Plan Proposal). 6. To approve, on a non-binding advisory basis, the compensation paid to the Companys named executive officers in 2024, as disclosed in the proxy statement (Proposal 6 or the Say-on-Pay Proposal). 7. To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of more than 19.99% of our outstandi","filed_date":"2025-07-03","accession":"0000950170-25-093924","full_text":"https://origin.rootz.global/static/filing/0000950170-25-093924.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"qualification necessary, except to the extent that the failure to be so qualified or be in good standing has not had and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. Section 4.02 Authorization, Enforcement, Compliance with Other Instruments. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreemen","filed_date":"2025-06-17","accession":"0000950170-25-087368","full_text":"https://origin.rootz.global/static/filing/0000950170-25-087368.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2025-05-15","accession":"0000950170-25-072622","full_text":"https://origin.rootz.global/static/filing/0000950170-25-072622.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"er Free Writing Prospectus” shall mean an issuer free writing prospectus, as defined in Rule 433. “Losses” shall have the meaning ascribed to such term in Section 7(d). 2 “Material Adverse Effect” shall have the meaning ascribed to such term in Section 3(b). “Material Permits” shall have the meaning ascribed to such term in Section 3(t). “Net Proceeds” shall","filed_date":"2025-04-28","accession":"0000950170-25-058966","full_text":"https://origin.rootz.global/static/filing/0000950170-25-058966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":77,"context":"ects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not effectively carry out their contractual duties, comply with re","filed_date":"2025-02-14","accession":"0000950170-25-020467","full_text":"https://origin.rootz.global/static/filing/0000950170-25-020467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":45,"context":"ws for 2024 and 2023 compensation awarded to or paid to, or earned by, the Company's Chief Executive Officer and its two other most highly compensated executive officers as of December 31, 2024 (the \"named executive officers\"). | | | Name and Principal Position | | Year | | Salary | | | EquityAwards(1) | | | Non-Equity Incentive Plan Compensation(2) | | | All OtherCompensation(3) | | | Total | | | |","filed_date":"2025-02-14","accession":"0000950170-25-020467","full_text":"https://origin.rootz.global/static/filing/0000950170-25-020467.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2024-11-07","accession":"0000950170-24-122837","full_text":"https://origin.rootz.global/static/filing/0000950170-24-122837.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2024-08-08","accession":"0000950170-24-093366","full_text":"https://origin.rootz.global/static/filing/0000950170-24-093366.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":34,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Companys businesses, results of o","filed_date":"2024-05-08","accession":"0000950170-24-055096","full_text":"https://origin.rootz.global/static/filing/0000950170-24-055096.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":58,"context":", 2024. 3. To approve the Aptevo Therapeutics Inc. Second Amended and Restated 2018 Stock Incentive Plan. 4. To approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers in 2023, as disclosed in the proxy statement. 5. To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in the proxy statement acc","filed_date":"2024-04-23","accession":"0000950170-24-046881","full_text":"https://origin.rootz.global/static/filing/0000950170-24-046881.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":77,"context":"ects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not effectively carry out their contractual duties, comply with re","filed_date":"2024-03-05","accession":"0000950170-24-025428","full_text":"https://origin.rootz.global/static/filing/0000950170-24-025428.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":46,"context":"nitiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our stockholders. We may choose to initiate, or may become subject to,","filed_date":"2024-03-05","accession":"0000950170-24-025428","full_text":"https://origin.rootz.global/static/filing/0000950170-24-025428.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":52,"context":"d 2022 compensation awarded to or paid to, or earned by, the Company’s Chief Executive Officer and its two other most highly compensated executive officers as of December 31, 2022 (the “named executive officers”). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Name and Principal Position | | Year | | Salary | | | Bonus(1) | | | EquityAwards(2) | |","filed_date":"2023-12-22","accession":"0000950170-23-072644","full_text":"https://origin.rootz.global/static/filing/0000950170-23-072644.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Company’s businesses, resu","filed_date":"2023-11-14","accession":"0000950170-23-063379","full_text":"https://origin.rootz.global/static/filing/0000950170-23-063379.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Company’s businesses, resu","filed_date":"2023-08-10","accession":"0000950170-23-040983","full_text":"https://origin.rootz.global/static/filing/0000950170-23-040983.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"nt” means the Lock-Up Agreements, each dated as of the date hereof, by and between the Company and the directors and officers of the Company, in the form of Exhibit A attached hereto. “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). “Material Permits” shall have the meaning ascribed to such term in Section 3.1(n). “OFAC” shall hav","filed_date":"2023-08-07","accession":"0000950170-23-038673","full_text":"https://origin.rootz.global/static/filing/0000950170-23-038673.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Company’s businesses, resu","filed_date":"2023-05-11","accession":"0000950170-23-020870","full_text":"https://origin.rootz.global/static/filing/0000950170-23-020870.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":60,"context":"the Company’s independent registered public accounting firm for the year ending December 31, 2023. 3. To approve, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers in 2022, as disclosed in the proxy statement. 4. To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in the proxy statement acc","filed_date":"2023-04-18","accession":"0000950170-23-013175","full_text":"https://origin.rootz.global/static/filing/0000950170-23-013175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"ects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. 23 • We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not effectively carry out their contractual duties, co","filed_date":"2023-03-30","accession":"0000950170-23-010757","full_text":"https://origin.rootz.global/static/filing/0000950170-23-010757.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ed consolidated balance sheet. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. Note 7. Liability Related to Sale of Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold to HCR t","filed_date":"2022-11-10","accession":"0001564590-22-037287","full_text":"https://origin.rootz.global/static/filing/0001564590-22-037287.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ed consolidated balance sheet. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. Note 7. Liability Related to Sale of Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold to HCR t","filed_date":"2022-08-11","accession":"0001564590-22-029025","full_text":"https://origin.rootz.global/static/filing/0001564590-22-029025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ed consolidated balance sheet. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. 10 Note 7. Liability Related to Sale of Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold to HC","filed_date":"2022-05-12","accession":"0001564590-22-019685","full_text":"https://origin.rootz.global/static/filing/0001564590-22-019685.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":57,"context":"ecember 31, 2022. 3. To approve the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated). 4. To approve, on a non-binding advisory basis, the compensation paid to the Companys named executive officers in 2021, as disclosed in the proxy statement. 5. To approve, on a non-bindingadvisory basis, the frequency of future advisory votes to approve named executive officer compensation. 6. To conduct any","filed_date":"2022-04-27","accession":"0001564590-22-015884","full_text":"https://origin.rootz.global/static/filing/0001564590-22-015884.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"ects or other unexpected properties of our product candidates may be identified that could delay, prevent, or cause the withdrawal of regulatory approval, limit the commercial potential, or result in significant negative consequences following marketing approval. | | | | | We depend on third parties to conduct our clinical and non-clinical trials. If these third parties do not effectively carry out their contractual duties, c","filed_date":"2022-03-24","accession":"0001564590-22-011575","full_text":"https://origin.rootz.global/static/filing/0001564590-22-011575.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ompany with the SEC pursuant to Rule 424(b)(5) under the Securities Act and in accordance with Section 5(a) hereof, together with all documents and information incorporated therein by reference. (cc) Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its subsidiaries, t","filed_date":"2022-02-17","accession":"0001564590-22-005567","full_text":"https://origin.rootz.global/static/filing/0001564590-22-005567.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"al beginning on March 1, 2022. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. Note 7. Liability Related to Sale of Future Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold t","filed_date":"2021-11-12","accession":"0001564590-21-056494","full_text":"https://origin.rootz.global/static/filing/0001564590-21-056494.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"al beginning on March 1, 2022. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. Note 7. Liability Related to Sale of Future Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold t","filed_date":"2021-08-12","accession":"0001564590-21-043955","full_text":"https://origin.rootz.global/static/filing/0001564590-21-043955.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ng principal on March 1, 2022. This facility is subject to a subjective acceleration clause that could be invoked by MidCap Financial upon the occurrence of any event MidCap Financial deems to have a material adverse effect on our ability to repay the lender. Note 7. Liability Related to Sale of Future Royalties In March 2021, we entered into and closed the Royalty Purchase Agreement with HCR pursuant to which we sold t","filed_date":"2021-05-11","accession":"0001564590-21-026319","full_text":"https://origin.rootz.global/static/filing/0001564590-21-026319.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":39,"context":"goals and objectives relevant to the compensation of our executive officers; (2) determining the compensation of our chief executive officer; (3) reviewing and approving the compensation of our other named 10 executive officers; (4) overseeing the evaluation of our senior executives; (5) overseeing and administering our cash and equity incentive plans; and (6) preparing the compensation committee report, if required by SEC","filed_date":"2021-04-28","accession":"0001564590-21-021366","full_text":"https://origin.rootz.global/static/filing/0001564590-21-021366.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"ome of our clinical sites were at reduced capacity or closed, as well as our participation in the BEAT AML trial being delayed by the Leukemia and Lymphoma Society. These and other factors may have a material adverse effect on our business, results of operations and financial condition. Our future income will depend, in part, on the ability of Medexus to successfully further develop, market and commercialize IXINITY, r","filed_date":"2021-03-31","accession":"0001564590-21-016875","full_text":"https://origin.rootz.global/static/filing/0001564590-21-016875.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"ort appears in the Registration Statement and the Prospectus, and Moss Adams LLP are independent public accountants as required by the Securities Act and the Public Accounting Oversight Board. (ix)No Material Adverse Effect. The Company and each of its subsidiaries (as defined in Rule 405 under the Securities Act) has been duly organized, validly existing and in good standing under the laws of their respective jurisdict","filed_date":"2020-12-14","accession":"0001564590-20-056954","full_text":"https://origin.rootz.global/static/filing/0001564590-20-056954.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"e Note 12 Subsequent Events. Additionally, this facility is subject to a subjective acceleration clause that could be invoked by the lender upon the occurrence of any event the lender deems to have a material adverse effect on our ability to repay the lender. Note 7. Leases Office Space Lease Operating We have an operating lease related to our office and laboratory space in Seattle, Washington. This lease was amended an","filed_date":"2020-11-10","accession":"0001564590-20-053058","full_text":"https://origin.rootz.global/static/filing/0001564590-20-053058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. You should carefully consider the following risks and other information in this Quarterly Report on Form 10-Q","filed_date":"2020-08-14","accession":"0001564590-20-040295","full_text":"https://origin.rootz.global/static/filing/0001564590-20-040295.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. You should carefully consider the following risks and other information in this quarterly report on Form 10-Q","filed_date":"2020-05-13","accession":"0001564590-20-025066","full_text":"https://origin.rootz.global/static/filing/0001564590-20-025066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition and results of operations. The cost of defending any products liability litigation or other proceeding, even if resolved in our favor, could be substantial. Uncer","filed_date":"2020-03-25","accession":"0001564590-20-012791","full_text":"https://origin.rootz.global/static/filing/0001564590-20-012791.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ations under the Amended Credit Agreement. This facility is subject to a subjective acceleration clause that could be invoked by the lender upon the occurrence of any event the lender deems to have a material adverse effect on our ability to repay the lender. As a result of the uncertainty related to our ability to continue as a going concern and the assessment that the material adverse change clause under the Amended C","filed_date":"2019-11-07","accession":"0001564590-19-041524","full_text":"https://origin.rootz.global/static/filing/0001564590-19-041524.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"he Amended Credit Agreement. Additionally, this facility is subject to a subjective acceleration clause that could be invoked by the lender upon the occurrence of any event the lender deems to have a material adverse effect on our ability to repay the lender. The obligations under the Amended Credit Agreement will mature on February 1, 2023. Amounts drawn under the Amended Credit Agreement continue to accrue interest a","filed_date":"2019-08-09","accession":"0001564590-19-031118","full_text":"https://origin.rootz.global/static/filing/0001564590-19-031118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"claims, our intellectual property or other third-party claims. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows. Item 1A. Risk Factors. You should carefully consider the following risks and other information in this quarterly report on Form 10-Q","filed_date":"2019-05-09","accession":"0001564590-19-017616","full_text":"https://origin.rootz.global/static/filing/0001564590-19-017616.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"and | | | | • | our success and the success of our third-party distributors in selling and marketing IXINITY. | | The failure to maximize the financial contribution of IXINITY could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We may choose to increase the price of IXINITY, and these price adjustments may negatively affect our sales volumes.","filed_date":"2019-03-18","accession":"0001564590-19-008184","full_text":"https://origin.rootz.global/static/filing/0001564590-19-008184.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"aws of their respective jurisdictions of organization, except where the failure to be so duly organized, duly organized, validly existing and in good standing would not reasonably be expected to have Material Adverse Effect (as defined below). The Company and each of its subsidiaries are, and will be, duly licensed or qualified as a foreign corporation for the transaction of business and in good standing under the laws","filed_date":"2019-03-11","accession":"0001193125-19-070196","full_text":"https://origin.rootz.global/static/filing/0001193125-19-070196.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"full proportionate adjustment thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction. (gg)Material Adverse Effect means any material adverse effect on (i)the enforceability of any Transaction Document, (ii)the results of operations, assets, business or financial condition of the Company and its Subsidiaries, tak","filed_date":"2018-12-24","accession":"0001564590-18-031354","full_text":"https://origin.rootz.global/static/filing/0001564590-18-031354.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":55,"context":"involves a minor violation that would not be subject to legal action by the FDA or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc. Material Adverse Effect means with respect to any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), whe","filed_date":"2018-11-14","accession":"0001564590-18-029562","full_text":"https://origin.rootz.global/static/filing/0001564590-18-029562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ified as available-for-sale. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the realized value of our investment portfolio. We actively monitor changes in interest rates and, with our current portfolio of short term investments, we are not exposed to potential loss due to","filed_date":"2018-08-09","accession":"0001564590-18-020781","full_text":"https://origin.rootz.global/static/filing/0001564590-18-020781.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ified as available-for-sale. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the realized value of our investment portfolio. We actively monitor changes in interest rates and, with our current portfolio of short term investments, we are not exposed to potential loss due to","filed_date":"2018-05-10","accession":"0001564590-18-012733","full_text":"https://origin.rootz.global/static/filing/0001564590-18-012733.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"APVO","company":"Aptevo Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"d | | | | • | our success and the success of our third-party distributors in selling and marketing IXINITY. | | 20 The failure to maximize the financial contribution of IXINITY could have a material adverse effect on our business, financial condition, results of operations and growth prospects. We may choose to increase the price of IXINITY, and these price adjustments may negatively affect our sales volumes.","filed_date":"2018-03-13","accession":"0001564590-18-005384","full_text":"https://origin.rootz.global/static/filing/0001564590-18-005384.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"dc10b331ca8dfc6f369e3926d2fb490ab7791ab9ce21e69525c79bcde058f6ba","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"027a58f7e03232db777f94bc708fe47c3a30b783b4f59b4f025d9a1be9f51e22","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":175,"hourly_limit":500,"remaining":325,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}